Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Autoantibody

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    91 result(s) found for: Autoantibody. Displaying page 5 of 5.
    « Previous 1  2  3  4  5 
    EudraCT Number: 2020-003233-38 Sponsor Protocol Number: WA41937 Start Date*: 2021-03-02
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL ACTIVE COMPARATOR-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH PRIMARY MEMBRANOUS NEPHROPATHY
    Medical condition: Primary Membranous Nephropathy (pMN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004778-25 Sponsor Protocol Number: AIE001 Start Date*: 2021-06-08
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Gl...
    Medical condition: Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10072378 Encephalitis autoimmune PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) NL (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015929-37 Sponsor Protocol Number: 1001 Start Date*: 2010-09-02
    Sponsor Name:Andromeda Biotech Ltd, 42 Hayarkon st, Yavne, 81227, Israel
    Full Title: A PHASE III, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF DIAPEP277® IN NEWLY DIAGNOSED TYPE 1 DIABETES SUBJECTS
    Medical condition: Type I diabetes
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) DE (Completed) IT (Completed) AT (Completed) CZ (Completed) LT (Completed) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001729-25 Sponsor Protocol Number: RA0055 Start Date*: 2012-03-05
    Sponsor Name:UCB Pharma SA
    Full Title: A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol in combination with methotrexate for inducing and sustaining clinical re...
    Medical condition: Early active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IE (Completed) HU (Completed) ES (Completed) CZ (Completed) AT (Completed) SE (Completed) NL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002248-98 Sponsor Protocol Number: TN-10 Start Date*: 2016-01-15
    Sponsor Name:TrialNet Coordinating Center
    Full Title: Anti-CD3 mAb (teplizumab) for prevention of diabetes in relatives at-risk for Type 1 diabetes mellitus
    Medical condition: Anti-CD3 monoclonal antibody is to be used for the prevention of type 1 diabetes mellitus in relatives at risk for developing the disease.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10042613 - Surgical and medical procedures 10066284 Diabetes prophylaxis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000101-37 Sponsor Protocol Number: IM128-035 Start Date*: 2017-04-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Subjects with Moderate to Severe Primary ...
    Medical condition: subjects with moderate to severe Sjögren's syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10040766 Sjogren's disease LLT
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10042846 Syndrome Sjogren's LLT
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10040765 Sjogren's LLT
    19.1 10010331 - Congenital, familial and genetic disorders 10048676 Sjogren-Larsson syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000705-59 Sponsor Protocol Number: IMMU-103-03 Start Date*: 2005-06-07
    Sponsor Name:Immunomedics, Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    10042945
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prohibited by CA) ES (Completed) SK (Completed) IT (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-006550-96 Sponsor Protocol Number: TN-07 Start Date*: 2007-03-23
    Sponsor Name:NIDDK TYPE 1 DIABETES TRIALNET
    Full Title: Oral insulin for prevention of diabetes in relatives at risk for type 1 diabetes mellitus
    Medical condition: prevention of type 1 diabetes mellitus in subjects at risk for T1DM
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045228 Type I diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) FI (Completed) DE (Completed) GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000706-31 Sponsor Protocol Number: IMMU-103-04 Start Date*: 2005-05-13
    Sponsor Name:Immunomedics, Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    10042945
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prohibited by CA) BE (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000249-42 Sponsor Protocol Number: IMVT-1401-3101 Start Date*: 2022-10-12
    Sponsor Name:Immunovant Sciences GmbH
    Full Title: A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Genera...
    Medical condition: Generalized Myasthenia Gravis (gMG)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002541-63 Sponsor Protocol Number: IMP321-P011 Start Date*: 2015-12-21
    Sponsor Name:Immutep S.A.S.
    Full Title: AIPAC (Active Immunotherapy PAClitaxel): A multicentre, Phase IIb, randomised, double blind, placebo-controlled study in hormone receptor-positive metastatic breast carcinoma patients receiving IMP...
    Medical condition: Female metastasized oestrogen receptor positive and/or progesterone receptor positive breast adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) BE (Completed) HU (Completed) FR (Completed) DE (Completed) PL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 23:01:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA